DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 150+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the Non-Alcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Alcoholic Steatohepatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report

• DelveInsight’s Non-Alcoholic Steatohepatitis pipeline report depicts a robust space with 100+ active players working to develop 150+ pipeline therapies for Non-Alcoholic Steatohepatitis treatment.
• The leading companies working in the Non-Alcoholic Steatohepatitis Market include Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others
• Emerging Non-Alcoholic Steatohepatitis Pipeline Therapies in the various stages of development include hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others.
• December 2023: Novo Nordisk A/S announced a study of Phase 3 clinical trials for Semaglutide. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
• December 2023: Boehringer Ingelheim announced a study of Phase 2 clinical trials for BI 456906.This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine.
• November 2023: Gilead Sciences announced a study of Phase 2 clinical trials for Semaglutide (SEMA) and Cilofexor (CILO)/Firsocostat (FIR). The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.

 

Request a sample and discover the recent advances in Non-Alcoholic Steatohepatitis Treatment Drugs @ Non-Alcoholic Steatohepatitis Pipeline Outlook Report

 

In the Non-Alcoholic Steatohepatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Non-Alcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells.

 

Find out more about Non-Alcoholic Steatohepatitis Treatment Landscape @ Drugs for Non-Alcoholic Steatohepatitis Treatment

 

Non-Alcoholic Steatohepatitis Emerging Drugs Profile

• Resmetirom: Madrigal Pharmaceuticals
• MSDC-0602K: Cirius Therapeutics
• ION224: Ionis Pharmaceuticals
• HU 6: Rivus Pharmaceuticals
• HTD 1801: HighTide Biopharma
• EDP-305: Enanta Pharmaceuticals

 

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the therapies for Nonalcoholic Steatohepatitis. The Non-Alcoholic Steatohepatitis companies which have their Nonalcoholic Steatohepatitis drug candidates in the most advanced stage, i.e. phase III include, Madrigal Pharmaceuticals.

 

DelveInsight’s Non-Alcoholic Steatohepatitis Pipeline Report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Non-Alcoholic Steatohepatitis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule 

 

Learn more about the emerging Non-Alcoholic Steatohepatitis Pipeline Therapies @ Non-Alcoholic Steatohepatitis Clinical Trials Assessment

 

Scope of the Non-Alcoholic Steatohepatitis Pipeline Report

• Coverage- Global
• Non-Alcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Alcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Alcoholic Steatohepatitis Companies- Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others.
• Non-Alcoholic Steatohepatitis Therapies- hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others.

 

Dive deep into rich insights for new drugs for Non-Alcoholic Steatohepatitis Treatment, Visit @ Non-Alcoholic Steatohepatitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Non-Alcoholic Steatohepatitis Executive Summary
3. Nonalcoholic Steatohepatitis: Overview
4. Non-Alcoholic Steatohepatitis Pipeline Therapeutics
5. Non-Alcoholic Steatohepatitis Therapeutic Assessment
6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Resmetirom: Madrigal Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ION224: Ionis Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AMG 609: Amgen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nonalcoholic Steatohepatitis Key Companies
21. Nonalcoholic Steatohepatitis Key Products
22. Nonalcoholic Steatohepatitis- Unmet Needs
23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
25. Nonalcoholic Steatohepatitis Analyst Views
26. Nonalcoholic Steatohepatitis Key Companies
27. Appendix

 

For further information on the Non-Alcoholic Steatohepatitis Pipeline Therapeutics, reach out @ Non-Alcoholic Steatohepatitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market